CCL5

CCL5 Full Name

chemokine (C-C motif) ligand 5

CCL5 Introduction

CCL5, also known as RANTES (Regulated upon Activation, Normal T Cell Expressed and Secreted), is a pro-inflammatory chemokine that has emerged as a critical regulator of immune cell trafficking, chronic inflammation, and tissue remodeling. Encoded by the CCL5 gene, this small secreted cytokine primarily interacts with receptors such as CCR1, CCR3, and especially CCR5 to coordinate the migration of T cells, macrophages, eosinophils, dendritic cells, and microglia toward sites of injury or infection. Researchers and drug developers are increasingly focused on the CCL5/CCR5 signaling axis because dysregulated chemokine signaling is closely associated with persistent inflammation, immune exhaustion, and disease progression across multiple therapeutic areas. Recent studies have demonstrated that CCL5 not only functions as a chemotactic mediator but also actively influences oxidative stress responses, cellular survival pathways, and immune polarization. For investigators exploring inflammatory signaling pathways, neuroimmune interactions, or targeted immunotherapy strategies, CCL5 represents a highly actionable biomarker and therapeutic target with broad translational relevance.

The biological functions of CCL5 extend far beyond classical immune recruitment, making it particularly important in cancer biology, neuroinflammation, and vascular disease research. In oncology, elevated CCL5 expression has been linked to tumor immune microenvironment remodeling, metastatic progression, and resistance to therapy in multiple cancer types. Pan-cancer analyses published in recent years suggest that the CCL5/CCR5 axis may serve as both a prognostic biomarker and a therapeutic intervention point, especially in tumors characterized by high immune infiltration and chronic inflammatory signaling. In the nervous system, growing evidence indicates that CCL5 contributes to microglial activation and neuroimmune communication following traumatic brain injury, HIV-associated neurocognitive disorders, and neurodegenerative conditions. Experimental findings show that recombinant CCL5 can regulate oxidative stress pathways, increase antioxidant enzyme expression such as SOD1, SOD2, and GPX1, and modulate M2-like microglial polarization through CCR5-dependent mechanisms. These discoveries are particularly valuable for researchers seeking novel strategies to control neuroinflammation while preserving neuronal survival and tissue repair capacity.

CCL5 is also increasingly recognized as a key mediator in cardiovascular and metabolic dysfunction, particularly in vascular aging and endothelial injury. Recent vascular biology studies demonstrated that adipose tissue-derived CCL5 promotes endothelial senescence, endothelial-to-mesenchymal transition, and nitric oxide signaling abnormalities through altered eNOS phosphorylation and oxidative stress activation. Such findings highlight why chronic elevation of inflammatory chemokines is now considered a major contributor to age-related cardiovascular decline and metabolic disease progression. Furthermore, the importance of the CCL5/CCR5 pathway in infectious disease remains highly significant, especially because CCR5 functions as a major co-receptor for HIV-1 entry into host immune cells. This dual role in antiviral immunity and pathological inflammation has accelerated the development of CCR5 antagonists, neutralizing antibodies, and chemokine-targeted therapeutic platforms. As precision medicine increasingly shifts toward immune-modulating therapies, CCL5 continues to gain attention as a multifunctional target capable of influencing cancer immunity, neurodegeneration, inflammatory disorders, and vascular pathology simultaneously.

Alternate Names for CCL5

CCL5; chemokine (C-C motif) ligand 5; SISd; eoCP; SCYA5; RANTES; TCP228; D17S136E; SIS-delta; C-C motif chemokine 5

• 1.Ho MH, et al.; CCL5/RANTES signaling in inflammation dysregulation after mild traumatic brain injury. J Biomed Sci. 2026, 33(1):10.
  2.Zhao W, et al.; Pan-cancer characterization of C-C motif chemokine ligand 5 (CCL5) identifies its role as biomarker and therapeutic target. Discov Oncol. 2025, 16(1):264.